$ATNF
180 Life Sciences Corp. Stock $atnf

$atnf Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023025521 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.009M	$5.054M	$15.36M
YoY Change	34.78%	102.94%	32.65%
% of Gross Profit
Research & Development	$578.3K	$585.7K	$2.192M
YoY Change	-18.16%	-70.29%	-44.49%
% of Gross Profit
Depreciation & Amortization	$21.77K	$37.60K	$109.0K
YoY Change	-17.72%	123.68%	-0.86%
% of Gross Profit
Operating Expenses	$4.804M	$5.640M	$17.90M
YoY Change	30.5%	26.4%	14.43%
Operating Profit	-$4.804M		-$17.90M
YoY Change	30.5%		14.43%
Interest Expense	$56.46K	$971.4K	$36.42K
YoY Change	-98.92%	-82.81%	-100.75%
% of Operating Profit
Other Income/Expense, Net	$41.77K	$0.00	-$21.77M
YoY Change	138.4%	-100.0%	2763.29%
Pretax Income	-$4.762M	-$22.69M	-$39.67M
YoY Change	-404.54%	-2303.29%	94.95%
Income Tax		-$942.8K	-$942.7K
% Of Pretax Income
Net Earnings	-$4.762M	-$21.74M	-$38.73M
YoY Change	-404.54%	-2198.23%	90.54%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.27		-$20.38
Diluted Earnings Per Share	-$1.27	-$9.75	-$18.55
COMMON SHARES
Basic Shares Outstanding	3.747M shares	40.46M shares	1.900M shares
Diluted Shares Outstanding	3.747M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.646M	$6.970M	$6.970M
YoY Change	-53.32%	-15.25%	-15.25%
Cash & Equivalents	$2.646M	$6.970M
Short-Term Investments
Other Short-Term Assets	$1.193M	$1.337M	$1.337M
YoY Change	-63.72%	-55.07%	-41.4%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.196M	$8.928M	$8.928M
YoY Change	-53.15%	-20.29%	-20.29%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$1.663M	$1.659M
YoY Change		-14.88%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$10.73M	$10.72M	$10.72M
YoY Change	-78.85%	-79.19%	-79.19%
TOTAL ASSETS
Total Short-Term Assets	$4.196M	$8.928M	$8.928M
Total Long-Term Assets	$10.73M	$10.72M	$10.72M
Total Assets	$14.92M	$19.65M	$19.65M
YoY Change	-74.99%	-68.67%	-68.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.208M	$1.801M	$1.801M
YoY Change	16.27%	207.05%	207.05%
Accrued Expenses	$2.821M	$2.285M	$2.473M
YoY Change	5.85%	15.21%	24.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due	$842.2K	$1.309M	$1.309M
YoY Change	-35.04%	-28.42%	-28.42%
Total Short-Term Liabilities	$5.122M	$5.658M	$5.658M
YoY Change	-66.03%	-71.28%	-71.28%
LONG-TERM LIABILITIES
Long-Term Debt	$28.73K	$31.19K	$31.19K
YoY Change	-34.12%	-35.25%	-35.25%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$28.73K	$31.19K	$31.19K
YoY Change	-61.53%	-35.25%	-35.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.122M	$5.658M	$5.658M
Total Long-Term Liabilities	$28.73K	$31.19K	$31.19K
Total Liabilities	$7.783M	$8.306M	$8.306M
YoY Change	-58.54%	-64.49%	-64.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$112.2M	-$107.4M
YoY Change		56.38%
Common Stock	$375.00	$375.00
YoY Change		-88.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.140M	$11.34M	$11.34M
YoY Change
Total Liabilities & Shareholders Equity	$14.92M	$19.65M	$19.65M
YoY Change	-74.99%	-68.67%	-68.67%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$4.762M	-$21.74M	-$38.73M
YoY Change	-404.54%	-2198.23%	90.54%
Depreciation, Depletion And Amortization	$21.77K	$37.60K	$109.0K
YoY Change	-17.72%	123.68%	-0.86%
Cash From Operating Activities	-$3.870M	-$2.927M	-$12.13M
YoY Change	86.69%	-41.79%	-37.39%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-469.8K	6.396M	$10.87M
YoY Change	-8.85%	312.88%	-57.21%
NET CHANGE
Cash From Operating Activities	-$3.870M	-2.927M	-$12.13M
Cash From Investing Activities
Cash From Financing Activities	-469.8K	6.396M	$10.87M
Net Change In Cash	-$4.324M	3.469M	-$1.254M
YoY Change	67.05%	-199.73%
FREE CASH FLOW
Cash From Operating Activities	-$3.870M	-$2.927M	-$12.13M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Other Income OtherIncome		usd
CY2021Q4	atnf	Preferred Stock Value1 PreferredStockValue1		usd
CY2021Q4	atnf	Preferred Stock Value2 PreferredStockValue2		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38105
CY2022	dei	Entity Registrant Name EntityRegistrantName	180 LIFE SCIENCES CORP.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-1890354
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3000 El Camino Real, Bldg. 4
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94306
CY2022	dei	City Area Code CityAreaCode	(650)
CY2022	dei	Local Phone Number LocalPhoneNumber	507-0669
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	ATNF
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	25377272	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3746906	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum, LLP
CY2022	dei	Auditor Location AuditorLocation	San Francisco, CA
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6970110	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	8224508	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1958280	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2976583	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8928390	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	11201091	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1658858	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1948913	usd
CY2022Q4	atnf	Inprocess Research And Development InprocessResearchAndDevelopment	9063000	usd
CY2021Q4	atnf	Inprocess Research And Development InprocessResearchAndDevelopment	12575780	usd
CY2021Q4	us-gaap	Goodwill Goodwill	36987886	usd
CY2022Q4	us-gaap	Assets Assets	19650248	usd
CY2021Q4	us-gaap	Assets Assets	62713670	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1801210	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	586611	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2284516	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1964580	usd
CY2022Q4	atnf	Accrued Expenses Related Parties AccruedExpensesRelatedParties	188159	usd
CY2021Q4	atnf	Accrued Expenses Related Parties AccruedExpensesRelatedParties	18370	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	1308516	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	1828079	usd
CY2021Q4	atnf	Loans Payable Related Parties LoansPayableRelatedParties	81277	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	75381	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15220367	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5657782	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19699284	usd
CY2022Q4	atnf	Loans Payable Non Current Portion LoansPayableNonCurrentPortion	31189	usd
CY2021Q4	atnf	Loans Payable Non Current Portion LoansPayableNonCurrentPortion	48165	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2617359	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3643526	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8306330	usd
CY2021Q4	us-gaap	Liabilities Liabilities	23390975	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3746906	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3746906	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1701799	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1701799	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	375	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	170	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121637611	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	107187371	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2885523	usd
CY2022	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty		usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	817440	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107408545	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68682286	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11343918	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	39322695	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19650248	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62713670	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2191834	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1000769	usd
CY2022	atnf	Research And Development Related Parties ResearchAndDevelopmentRelatedParties	240731	usd
CY2021	atnf	Research And Development Related Parties ResearchAndDevelopmentRelatedParties	2947536	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15459788	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11230118	usd
CY2022	atnf	General And Administrative Related Parties GeneralAndAdministrativeRelatedParties	5612	usd
CY2021	atnf	General And Administrative Related Parties GeneralAndAdministrativeRelatedParties	462580	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	17897965	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	15641003	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-17897965	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-15641003	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	926829	usd
CY2021	us-gaap	Other Income OtherIncome	-146822	usd
CY2022	atnf	Interest Expense Related Parties InterestExpenseRelatedParties	26667	usd
CY2021	atnf	Interest Expense Related Parties InterestExpenseRelatedParties	186208	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-9737	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	33547278	usd
CY2022	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-3342084	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-15144986	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4677388	usd
CY2021	atnf	Change In Fair Value Of Accrued Issuable Equity ChangeInFairValueOfAccruedIssuableEquity	9405	usd
CY2021	atnf	Offering Costs Allocated To Warrant Liabilities OfferingCostsAllocatedToWarrantLiabilities	604118	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21771043	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4706849	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39669008	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20347852	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-942749	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23204	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-38726259	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20324648	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-3702963	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	180554	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42429222	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20144094	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-20.38
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.96
CY2021	atnf	Offering Costs Allocated To Warrant Liabilities OfferingCostsAllocatedToWarrantLiabilities	604118	usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-15144986	usd
CY2021	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	4677388	usd
CY2021	atnf	Change In Fair Value Of Accrued Issuable Equity ChangeInFairValueOfAccruedIssuableEquity	9405	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1018303	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1377247	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1900397	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1567772	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	39322695	usd
CY2022	atnf	Issuance Of Prefunded Warrants IssuanceOfPrefundedWarrants	2562265	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	263	usd
CY2022	atnf	Shares Issued In Connection With Offering SharesIssuedInConnectionWithOffering	3407490	usd
CY2022	atnf	Issuance Of Prefunded Warrant IssuanceOfPrefundedWarrant	4823187	usd
CY2022	atnf	Shares Issued From Exercise Of Prefunded Warrants SharesIssuedFromExerciseOfPrefundedWarrants	150	usd
CY2022	atnf	Shares Issued In Connections With Offering SharesIssuedInConnectionsWithOffering	691673	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	331591	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2633826	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38726259	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3702963	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11343918	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	30286869	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	1941125	usd
CY2021	atnf	Shares Issued Upon Conversion Of180 Debt SharesIssuedUponConversionOf180Debt	432383	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10731070	usd
CY2021	atnf	Stock Issued During Period Value Offering Costs Allocated To Warrant Liabilities StockIssuedDuringPeriodValueOfferingCostsAllocatedToWarrantLiabilities	604118	usd
CY2021	atnf	Warrants Issued In Connection With Private Offering Reclassified To Derivative Liabilities WarrantsIssuedInConnectionWithPrivateOfferingReclassifiedToDerivativeLiabilities	-7294836	usd
CY2021	atnf	Shares Issued To Settle Accounts Payable SharesIssuedToSettleAccountsPayable	1973250	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	13880000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1060500	usd
CY2021	atnf	Shares Issued In Connection With The Repayment Of Related Party Loans And Convertible Notes SharesIssuedInConnectionWithTheRepaymentOfRelatedPartyLoansAndConvertibleNotes	851112	usd
CY2021	atnf	Stock Issued During Period Sharebased Compensation Common Stock StockIssuedDuringPeriodSharebasedCompensationCommonStock	2148889	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2852309	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20324648	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	180554	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	39322695	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38726259	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20324648	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	331591	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2148889	usd
CY2022	atnf	Amoritization Of Stock Options AmoritizationOfStockOptions	2633826	usd
CY2021	atnf	Amoritization Of Stock Options AmoritizationOfStockOptions	2852309	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	33547278	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	3342084	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	109004	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	109947	usd
CY2021	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	300000	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	926829	usd
CY2021	atnf	Loss On Extinguishment Of Convertible Note Payable LossOnExtinguishmentOfConvertibleNotePayable	9737	usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	942749	usd
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	24803	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1214599	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5515042	usd
CY2021	atnf	Increase Or Decrease In Accounts Payable Related Parties IncreaseOrDecreaseInAccountsPayableRelatedParties	-215495	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	319936	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1210076	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	169788	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-436581	usd
CY2021	atnf	Accrued Issuable Equitys AccruedIssuableEquitys	52500	usd
CY2022	atnf	Total Adjustments TotalAdjustments	26598674	usd
CY2021	atnf	Total Adjustments TotalAdjustments	953220	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12127585	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19371428	usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	26666200	usd
CY2021	atnf	Offering Costs In Connection With2021 Sale Of Stock And Warrants OfferingCostsInConnectionWith2021SaleOfStockAndWarrants	-2055130	usd
CY2022	atnf	Offering Costs In Connection With July2022 Sale Of Common Stock And Common Warrants OfferingCostsInConnectionWithJuly2022SaleOfCommonStockAndCommonWarrants	-529982	usd
CY2022	atnf	Offering Costs In Connection With Sale Of Common Stock And Warrants OfferingCostsInConnectionWithSaleOfCommonStockAndWarrants	-484991	usd
CY2022	atnf	Proceeds From Convertible Notes Payable ProceedsFromConvertibleNotesPayable	1060890	usd
CY2021	atnf	Proceeds From Convertible Notes Payable ProceedsFromConvertibleNotesPayable	1618443	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10000	usd
CY2022	atnf	Repayment Of Loans Payable RepaymentOfLoansPayable	1591035	usd
CY2021	atnf	Repayment Of Loans Payable RepaymentOfLoansPayable	375789	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	81277	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	431805	usd
CY2022	atnf	Proceeds From Sale Of Common Stock1 ProceedsFromSaleOfCommonStock1	6499737	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5999851	usd
CY2022	atnf	Proceeds From Exercise Of July2022 Prefunded Warrants ProceedsFromExerciseOfJuly2022PrefundedWarrants	-263	usd
CY2022	atnf	Proceeds From Exercise Of December2022 Prefunded Warrants ProceedsFromExerciseOfDecember2022PrefundedWarrants	-150	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10873606	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25411919	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-419	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75473	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1254398	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6115964	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8224508	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2108544	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6970110	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8224508	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	15060	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	35351	usd
CY2021	atnf	Common Stock Issued Upon Conversion Of Kbl Debt CommonStockIssuedUponConversionOfKBLDebt	1931388	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	432383	usd
CY2021	atnf	Deemed Dividend Beneficial Conversion Feature On Series A Convertible Preferred Stock DeemedDividendBeneficialConversionFeatureOnSeriesAConvertiblePreferredStock	851112	usd
CY2021	atnf	Shares Issued Due To Impact Of Transfer Agent Reconciliation SharesIssuedDueToImpactOfTransferAgentReconciliation	1013331	usd
CY2021	atnf	Exchange Of Common Stock Equivalents For Common Stock ExchangeOfCommonStockEquivalentsForCommonStock	146	usd
CY2021	atnf	Shares Cancelled SharesCancelled	1750000	usd
CY2021	atnf	Reclassification Of Accrued Issuable Equity ReclassificationOfAccruedIssuableEquity	43095	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - BUSINESS ORGANIZATION AND NATURE OF OPERATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Sciences Corp., formerly known as KBL Merger Corp. IV (“180LS”, or together with its subsidiaries, the “Company”), was a blank check company organized under the laws of the State of Delaware on September 7, 2016. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Corp. (“180”, f/k/a 180 Life Sciences Corp. and CannBioRx Life Sciences Corp.) is a wholly-owned subsidiary of the Company and was incorporated in the State of Delaware on January 28, 2019. The Company is located in the United States (“U.S.”) and is a medical pharmaceutical company focused upon unmet medical needs in the areas of inflammatory diseases, fibrosis, and chronic pain by employing innovative research and, where appropriate, combination therapies, through 180’s three wholly-owned subsidiaries, 180 Therapeutics L.P. (“180 LP”), CannBioRex Pharmaceuticals Corp. (“CBR Pharma”), and Katexco Pharmaceuticals Corp. (“Katexco”). 180 LP, CBR Pharma and Katexco are together, the “180 Subsidiaries.” Katexco was incorporated on March 7, 2018 under the provisions of the British Corporation Act of British Columbia. Additionally, 180’s wholly-owned subsidiaries Katexco Callco, ULC, Katexco Purchaseco, ULC, CannBioRex Callco, ULC, and CannBioRex Purchaseco, ULC were formed in the Canadian Province of British Columbia on May 31, 2019 to facilitate the acquisition of Katexco, CBR Pharma and 180 LP. On July 1, 2021, the assets and liabilities of the Canadian companies (Katexco and CBR Pharma) were transferred to their respective subsidiaries, which are Katexco Pharmaceuticals Corp. (“Katexco U.S.”) and CannBioRex Pharma Limited (“CBR Pharma U.K.”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis and other inflammatory diseases, where anti-TNF therapy will provide a clear benefit to patients, by employing innovative research, and, where appropriate, combination therapy. We have three product development platforms:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fibrosis and anti-tumor necrosis factor (“TNF”);</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drugs which are derivatives of cannabidiol (“CBD”); and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">alpha 7 nicotinic acetylcholine receptor (“α7nAChR”).</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Reverse Stock-Split during 2022</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 15, 2022, the Company held a special meeting of stockholders of the Company whereby the Company’s stockholders approved an amendment to the Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the issued and outstanding shares of common stock, par value $0.0001 per share, in a range of between one-for-four and one-for-twenty shares, in the discretion of the Board of Directors. The Board of Directors subsequently approved a reverse stock split in a ratio of one-for-twenty shares (the “Reverse Stock Split”). Pursuant to the Certificate of Amendment filed with the Secretary of State of Delaware to affect the Reverse Stock Split, with new CUSIP number: 68236V203. No change was made to the trading symbol for the Company’s shares of common stock or public warrants, “ATNF” and “ATNFW”, respectively, in connection with the Reverse Stock Split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the Certificate of Amendment did not reduce the number of authorized shares of common stock, the effect of the Reverse Stock Split was to increase the number of shares of common stock available for issuance relative to the number of shares issued and outstanding. The Reverse Stock Split did not alter the par value of the common stock or modify any voting rights or other terms of the common stock. Any fractional shares remaining after the Reverse Stock Split were rounded up to the nearest whole share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With regards to the Company’s 2020 Omnibus Incentive Plan and the 2022 Omnibus Incentive Plan, the Company’s Compensation Committee and Board deemed it in the best interests of the Company and its stockholders to (i) adjust the number of shares of Company common stock available for issuance under the Incentive Plans downward by a factor of 20 (with any fractional shares rounded down to the nearest whole share); (ii) reduce the number of shares of common stock issuable upon each outstanding option to purchase shares of common stock of the Company, and all other outstanding awards, by a factor of 20 (with any fractional shares rounded down to the nearest whole share); and (iii) adjust the exercise price of any outstanding options to purchase shares of common stock previously granted under the Incentive Plans up by a factor of 20 (rounded up to the nearest whole cent), in each case to adjust equitably for the exchange ratio of the Reverse Stock Split, which such adjustments effective automatically upon effectiveness of the Reverse Stock Split. The effects of the one-for-twenty reverse stock split have been retroactively reflected throughout the financial statements and notes to the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management continues to evaluate the impact of the COVID-19 pandemic and Russia-Ukraine war on the economy and the capital markets and has concluded that, while it is reasonably possible that such events could have negative effects on the Company’s financial position, the specific impacts are not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current challenging economic climate may lead to adverse changes in cash flows, working capital levels and/or debt balances, which may also have a direct impact on the Company’s future operating results and financial position. The ultimate duration and magnitude of the impact and the efficacy of government interventions on the economy and the financial effect on the Company is not known at this time. The extent of such impact will depend on future developments, which are highly uncertain and not in the Company’s control.</p>
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	atnf	Accumulated Deficit AccumulatedDeficit	107408545	usd
CY2022Q4	atnf	Working Capital Deficit WorkingCapitalDeficit	3270608	usd
CY2022	us-gaap	Profit Loss ProfitLoss	38726259	usd
CY2022	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	12127585	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the consolidated financial statements. The Company’s significant estimates and assumptions used in these financial statements include, but are not limited to, the fair value of financial instruments, warrants, options and derivative liabilities; R&D tax credits and accruals, and the estimates and assumptions related to the impairment analysis of goodwill and other intangible assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and may cause actual results to differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2022	atnf	Assets And Liabilities Exchange Rates Description AssetsAndLiabilitiesExchangeRatesDescription	The functional currency of certain subsidiaries is the Canadian Dollar (“CAD”) or British Pound (“GBP”). Assets and liabilities are translated based on the exchange rates at the balance sheet date (0.7369 and 0.7874 for the CAD, 1.2098 and 1.3510 for the GBP as of December 31, 2022 and 2021, respectively), while expense accounts are translated at the weighted average exchange rate for the period (0.7689 and 0.7977 for the CAD, and 1.2173 and 1.3753 for the GBP for the years ended December 31, 2022 and 2021, respectively). Equity accounts are translated at historical exchange rates. The resulting translation adjustments are recognized in stockholders’ equity as a component of accumulated other comprehensive income.
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-3702963	usd
CY2021	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	180554	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-12777	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-69	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	25079	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	162956	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	137050	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3435728	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	557695	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3598684	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	694745	shares
CY2022	atnf	Incurred Expenses incurredExpenses	2191834	usd
CY2021	atnf	Incurred Expenses incurredExpenses	1000769	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	240731	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2947536	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	49755	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1958280	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2976583	usd
CY2022	atnf	Litigation Receivable LitigationReceivable	1027292	usd
CY2021	atnf	Litigation Receivable LitigationReceivable	1937693	usd
CY2022	atnf	Research And Development Expense Tax Credit Receivable ResearchAndDevelopmentExpenseTaxCreditReceivable	546563	usd
CY2021	atnf	Research And Development Expense Tax Credit Receivable ResearchAndDevelopmentExpenseTaxCreditReceivable	644513	usd
CY2022	atnf	Professional Feeses ProfessionalFeeses	310017	usd
CY2021	atnf	Professional Feeses ProfessionalFeeses	294577	usd
CY2022Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	48774	usd
CY2021Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	24411	usd
CY2022Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	25634	usd
CY2021Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	25634	usd
CY2021	us-gaap	Other Expenses OtherExpenses	213974	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2081418	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-422560	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1658858	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2262469	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-313556	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1948913	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	109004	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116297	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	109489	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	109489	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	109489	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	109489	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	109489	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1111413	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1658858	usd
CY2021	atnf	Traded Stock TradedStock	78
CY2022Q1	atnf	Market Value Of Traded Stock MarketValueOfTradedStock	51.8	usd
CY2022Q2	atnf	Market Value Of Traded Stock MarketValueOfTradedStock	16.96	usd
CY2022Q3	atnf	Market Value Of Traded Stock MarketValueOfTradedStock	13.3	usd
CY2022Q4	atnf	Market Value Of Traded Stock MarketValueOfTradedStock	3.39	usd
CY2022Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	18872850	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	14674428	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	33547278	usd
CY2022Q4	us-gaap	Amount Of Impairment To Carrying Amount Of Regulatory Assets AmountOfImpairmentToCarryingAmountOfRegulatoryAssets	12405084	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	9063000	usd
CY2022	atnf	Impairment Of Intangible Asset Finitelived ImpairmentOfIntangibleAssetFinitelived	3342084	usd
CY2022	us-gaap	Impaired Intangible Asset Description ImpairedIntangibleAssetDescription	This reduced the IP R&D asset balances of its CBR Pharma subsidiary and its 180 LP subsidiary to zero and $9,063,000, respectively, as of December 31, 2022; the total consolidated IP R&D asset balance is $9,063,000 after impairment.
CY2022Q4	atnf	Number Of Warrants Exercised NumberOfWarrantsExercised	-1630890	shares
CY2022	atnf	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	0.0001
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022	atnf	Consulting Fees ConsultingFees	531829	usd
CY2021	atnf	Consulting Fees ConsultingFees	548281	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	3945	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	252973	usd
CY2022	atnf	Litigation Accrual LitigationAccrual	125255	usd
CY2021	atnf	Litigation Accrual LitigationAccrual	300000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1558024	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	725569	usd
CY2022	atnf	Research And Development Fees ResearchAndDevelopmentFees	22023	usd
CY2021	atnf	Research And Development Fees ResearchAndDevelopmentFees	91737	usd
CY2022	us-gaap	Interest Expense InterestExpense	36422	usd
CY2021	us-gaap	Interest Expense InterestExpense	25433	usd
CY2022	atnf	Other Accrued Liabilities OtherAccruedLiabilities	-7018	usd
CY2021	atnf	Other Accrued Liabilities OtherAccruedLiabilities	-20587	usd
CY2022	atnf	Accrued Liabilities AccruedLiabilities	2284516	usd
CY2021	atnf	Accrued Liabilities AccruedLiabilities	1964580	usd
CY2022	atnf	Related Party Expenses RelatedPartyExpenses	188159	usd
CY2021	atnf	Related Party Expenses RelatedPartyExpenses	18370	usd
CY2022	atnf	Acrued Issuable Equity Textblock AcruedIssuableEquityTextblock	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 - ACCRUED ISSUABLE EQUITY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the accrued issuable equity activity during the year ended December 31, 2021 is presented below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Balance at January 1, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,095</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Reclassification to equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December 31, 2020, the Company entered into a contractual arrangement for services in exchange for shares of common stock of the Company for fixed dollar amounts. Pursuant to the contractual agreement, the Company will issue an aggregate value of $5,000 of common shares on a monthly basis and an aggregate of $30,000 of common shares at the end of each quarter. As of December 31, 2020, the Company recorded $43,095 of accrued issuable equity related to services. During the first quarter of 2021, this balance was reclassified to equity and as of December 31, 2021, there was no accrued issuable equity.</p>
CY2022Q4	atnf	Number Of Warrants Outstanding NumberOfWarrantsOutstanding	3435728	shares
CY2022Q4	atnf	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	33.94
CY2022	atnf	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P5Y1M6D
CY2022Q4	atnf	Number Of Warrants Exercisable Balance NumberOfWarrantsExercisableBalance	577695	shares
CY2022	atnf	Loss On Extinguishment Of Convertible Note Payable LossOnExtinguishmentOfConvertibleNotePayable		usd
CY2020Q4	atnf	Accrued Issuable Equity Balance AccruedIssuableEquityBalance	43095	usd
CY2021	atnf	Reclassification To Equity ReclassificationToEquity	-43095	usd
CY2020	atnf	Aggregate Value Of Common Shares On Monthly Basis AggregateValueOfCommonSharesOnMonthlyBasis	5000	usd
CY2020	atnf	Aggregate Value Of Common Shares At End Of Each Quarter AggregateValueOfCommonSharesAtEndOfEachQuarter	30000	usd
CY2020	atnf	Accrued Issuable Equity Related To Services AccruedIssuableEquityRelatedToServices	43095	usd
CY2021Q4	atnf	Derivative Liability Balance DerivativeLiabilityBalance	15220367	usd
CY2022	atnf	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-15144986	usd
CY2022Q4	atnf	Derivative Liability Balance DerivativeLiabilityBalance	75381	usd
CY2020Q4	atnf	Derivative Liabilitie DerivativeLiabilitie	4442970	usd
CY2021	atnf	Extinguishment Of Derivative Liabilities In Connection With Conversion Of Debt ExtinguishmentOfDerivativeLiabilitiesInConnectionWithConversionOfDebt	-591203	usd
CY2021	atnf	Warrants Issued In Connection With The Financing WarrantsIssuedInConnectionWithTheFinancing	7294836	usd
CY2021	atnf	Warrants Issued Relates To Alpha Settlement WarrantsIssuedRelatesToAlphaSettlement	95677	usd
CY2021	atnf	Extinguishment Of Derivative Liabilities In Connection With The Alpha Settlement ExtinguishmentOfDerivativeLiabilitiesInConnectionWithTheAlphaSettlement	-699301	usd
CY2021	atnf	Change In Fair Values Of Derivative Liabilities ChangeInFairValuesOfDerivativeLiabilities	4677388	usd
CY2021Q4	atnf	Derivative Liabilitie DerivativeLiabilitie	15220367	usd
CY2022Q4	atnf	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice1	181.28
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y1M6D
CY2021Q3	us-gaap	Product Liability Contingency Loss Exposure In Excess Of Accrual Best Estimate ProductLiabilityContingencyLossExposureInExcessOfAccrualBestEstimate	11286570	usd
CY2022	atnf	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Credit Risk Derivative Liabilities At Fair Value CreditRiskDerivativeLiabilitiesAtFairValue	6474200	usd
CY2021Q1	atnf	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0059	pure
CY2021Q1	atnf	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y
CY2021Q1	atnf	Fair Value Assumptions Weighted Average Volatility Rate FairValueAssumptionsWeightedAverageVolatilityRate	0.85	pure
CY2021Q1	atnf	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate	0	pure
CY2021Q1	atnf	Beneficial Ownership BeneficialOwnership	0.0499	pure
CY2022	atnf	Warrant Revalued WarrantRevalued	400	usd
CY2021Q1	atnf	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0068	pure
CY2021Q1	atnf	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P3Y10M2D
CY2021Q1	atnf	Fair Value Assumptions Weighted Average Volatility Rate FairValueAssumptionsWeightedAverageVolatilityRate	0.85	pure
CY2021Q1	atnf	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate	0	pure
CY2022	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	0	usd
CY2022	atnf	Fair Value Of Warrants FairValueOfWarrants	43561	usd
CY2021Q3	atnf	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0037	pure
CY2021Q3	atnf	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P3Y
CY2021Q3	atnf	Fair Value Assumptions Weighted Average Volatility Rate FairValueAssumptionsWeightedAverageVolatilityRate	0.85	pure
CY2021Q3	atnf	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate	0	pure
CY2021Q1	atnf	Fair Value Assumption Expected Dividend Rate FairValueAssumptionExpectedDividendRate	0	pure
CY2020Q4	atnf	Number Of Warrants Outstanding NumberOfWarrantsOutstanding	303245	shares
CY2020Q4	atnf	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	228.69
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M24D
CY2021	atnf	Number Of Warrants Issued NumberOfWarrantsIssued	254450	shares
CY2021	atnf	Weighted Average Exercises Price Issued WeightedAverageExercisesPriceIssued	124.77
CY2021Q4	atnf	Number Of Warrants Outstanding NumberOfWarrantsOutstanding	577695	shares
CY2021Q4	atnf	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	181.2
CY2021	atnf	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P4Y1M6D
CY2022	atnf	Number Of Warrants Issued NumberOfWarrantsIssued	4508923	shares
CY2022	atnf	Weighted Average Exercises Price Issued WeightedAverageExercisesPriceIssued	3.44
CY2022	atnf	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Life In Years Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLifeInYearsIssued	P5Y4M24D
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3435728	shares
CY2022	atnf	Warrants Exercisable Weighted Average Remaining Life In Years WarrantsExercisableWeightedAverageRemainingLifeInYears	P3Y1M6D
CY2022	atnf	Warrants Exercisable Number Of Shares WarrantsExercisableNumberOfShares	577695	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	577695	shares
CY2021	atnf	Warrants Exercisable Weighted Average Remaining Life In Years WarrantsExercisableWeightedAverageRemainingLifeInYears	P4Y1M6D
CY2021	atnf	Warrants Exercisable Number Of Shares WarrantsExercisableNumberOfShares	577695	shares
CY2021Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	1876244	usd
CY2022	atnf	Adjustments Amount AdjustmentsAmount	66324	usd
CY2022	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1657359	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1060890	usd
CY2022	atnf	Effect Of Foreign Exchange Rates EffectOfForeignExchangeRates	-6394	usd
CY2022Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	1339705	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	1828079	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	1308516	usd
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	48165	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	31189	usd
CY2020Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	1082209	usd
CY2021	atnf	Adjustments Amount AdjustmentsAmount	-11670	usd
CY2021	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	810386	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1618443	usd
CY2021	atnf	Effect Of Foreign Exchange Rates EffectOfForeignExchangeRates	-2352	usd
CY2021Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	1876244	usd
CY2020Q4	us-gaap	Loans Payable Current LoansPayableCurrent	968446	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	1828079	usd
CY2020Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	113763	usd
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	48165	usd
CY2019Q4	atnf	Bridge Notes Interest Rate BridgeNotesInterestRate	0.15	pure
CY2020Q1	atnf	Bridge Notes Interest Rate BridgeNotesInterestRate	0.15	pure
CY2021	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	Pursuant to the terms of the Amended Bridge Notes, the principal under each Amended Bridge Note is increased by 10%, which can be converted; the number of conversion shares is equal to (A) the outstanding principal amount plus interest being converted, divided by (B) the lesser of (i) $4.23 per share or (ii) the per share price equal to 0.60 multiplied by the per share price of one share of common stock sold by the Company as part of a PIPE transaction.
CY2020Q4	atnf	Percentage Of Amendment Or Modification In Cash Flows PercentageOfAmendmentOrModificationInCashFlows	0.10	pure
CY2022	atnf	Loans Payable Current Portions LoansPayableCurrentPortions	1308516	usd
CY2021	atnf	Loans Payable Current Portions LoansPayableCurrentPortions	1828079	usd
CY2022	atnf	Loans Payable Non Current Portions LoansPayableNonCurrentPortions	43129	usd
CY2021	atnf	Loans Payable Non Current Portions LoansPayableNonCurrentPortions	102482	usd
CY2022	atnf	Current Portion Of Ppp Loan CurrentPortionOfPPPLoan	-11940	usd
CY2021	atnf	Current Portion Of Ppp Loan CurrentPortionOfPPPLoan	-54317	usd
CY2022	atnf	Totalloanspayable Totalloanspayable	31189	usd
CY2021	atnf	Totalloanspayable Totalloanspayable	48165	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	1636	usd
CY2022Q2	us-gaap	Prepaid Rent PrepaidRent	41312	usd
CY2020Q2	atnf	Maximum Loan Amount MaximumLoanAmount	50000	gbp
CY2022	atnf	Accrued Interest AccruedInterest	778	gbp
CY2022	atnf	Accrued Interest AccruedInterest	1051	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	778	gbp
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000	usd
CY2020Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.15	pure
CY2020Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2021-08-31
CY2021Q1	atnf	Aggregate Amount aggregateAmount	162452	usd
CY2021Q1	atnf	Aggregate Principal Amount AggregatePrincipalAmount	150000	usd
CY2021Q1	atnf	Accrued Interest AccruedInterest	12452	usd
CY2021	atnf	Bounce Back Loan Scheme BounceBackLoanScheme	4724	usd
CY2021Q4	atnf	First Assurance Funding To Finance FirstAssuranceFundingToFinance	1618443	usd
CY2021Q4	atnf	Insurance Value InsuranceValue	2005502	usd
CY2022Q4	atnf	Adjusted A Portion Loan Amount AdjustedAPortionLoanAmount	1060890	usd
CY2022	atnf	Monthly Installment Loans MonthlyInstallmentLoans	161844	usd
CY2022	atnf	Loan Payable Percentage LoanPayablePercentage	0.10	pure
CY2022	us-gaap	Legal Fees LegalFees	125255	usd
CY2021	atnf	Related Party Loans RelatedPartyLoans	81277	usd
CY2021Q1	atnf	Aggregate Principal Amount AggregatePrincipalAmount	432699	usd
CY2022Q4	atnf	Exchange An Aggregate Principal Amount ExchangeAnAggregatePrincipalAmount	433374	usd
CY2022Q4	atnf	Aggregate Accrued Interest aggregateAccruedInterest	61530	usd
CY2022Q4	atnf	Aggregate Shares1 AggregateShares1	4124	shares
CY2022	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	120
CY2022	atnf	Interest Expense On Loans Payable Description InterestExpenseOnLoansPayableDescription	For the year ended December 31, 2022, the Company recognized interest expense and interest income — related parties associated with outstanding loans, of $14,156 and $1,490, respectively. For the year ended December 31, 2021, the Company recognized interest expense and interest expense — related parties associated with outstanding loans, of $24,019 and $38,874, respectively. As of December 31, 2022, the Company had accrued interest and accrued interest — related parties associated with outstanding loans, of $37,960 and $16,770, respectively. See Note 14 — Related Parties for additional details. As of December 31, 2021, the Company had accrued interest and accrued interest — related parties associated with outstanding loans, of $24,212 and $812, respectively. See Note 14 — Related Parties for additional details.
CY2021	atnf	Interest Expense On Convertible Debt InterestExpenseOnConvertibleDebt	0	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	0	usd
CY2019Q4	atnf	Aggregate Of Shares Of Common Stock Description AggregateOfSharesOfCommonStockDescription	the holders of the Company’s convertible bridge notes, which were issued on December 27, 2019 and January 3, 2020 to various purchasers, converted an aggregate of $432,384, which included accrued interest of $66,633 owed under such convertible bridge notes, into an aggregate of 7,920 shares of common stock pursuant to the terms of such notes, as amended, at a conversion price of $54.60 per share.
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	260000	usd
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	96208	usd
	atnf	Converted Into Common Stock ConvertedIntoCommonStock	2969	shares
CY2020Q2	us-gaap	Secured Debt SecuredDebt	1657522	usd
CY2020Q2	atnf	Secured Convertible Promissory Note Percentage SecuredConvertiblePromissoryNotePercentage	0.10	pure
CY2020Q2	us-gaap	Senior Notes SeniorNotes	138889	usd
CY2020Q2	atnf	Senior Secured Convertible Promissory Note Percentage SeniorSecuredConvertiblePromissoryNotePercentage	0.10	pure
CY2020Q2	us-gaap	Shares Issued SharesIssued	1250	shares
CY2020Q2	atnf	Debt Discount DebtDiscount	685615	usd
CY2021	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	105.6
CY2020Q3	atnf	Secured Convertible Promissory Notepercentage SecuredConvertiblePromissoryNotepercentage	0.10	pure
CY2020Q3	us-gaap	Shares Issued SharesIssued	5000	shares
CY2020Q3	atnf	Debt Discount DebtDiscount	800421	usd
CY2021Q3	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	1234333	usd
CY2021Q3	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	105850	usd
CY2021Q3	us-gaap	Shares Issued SharesIssued	23357	shares
CY2021Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	1941124	usd
CY2021Q1	us-gaap	Secured Debt SecuredDebt	7500	usd
CY2021Q1	atnf	Secured Convertible Promissory Note Percentage SecuredConvertiblePromissoryNotePercentage	12.50	pure
CY2021Q1	atnf	Common Stock Exercise Price CommonStockExercisePrice	141.4
CY2021Q3	atnf	Share Warrants Aggregate Value ShareWarrantsAggregateValue	1156177	usd
CY2021Q3	atnf	Fair Value Of The Common Stock FairValueOfTheCommonStock	1060500	usd
CY2021Q3	atnf	Fair Value Of The Alpha Warrant FairValueOfTheAlphaWarrant	95677	usd
CY2020Q1	us-gaap	Notes Issued1 NotesIssued1	82500	usd
CY2019Q4	us-gaap	Notes Issued1 NotesIssued1	250000	usd
CY2020Q1	atnf	Aggregate Outstanding Principal Of Convertible Notes AggregateOutstandingPrincipalOfConvertibleNotes	332500	usd
CY2019Q4	atnf	Aggregate Outstanding Principal Of Convertible Notes AggregateOutstandingPrincipalOfConvertibleNotes	332500	usd
CY2020Q1	atnf	Kbl Common Stock KblCommonStock	17500000	shares
CY2019Q4	atnf	Kbl Common Stock KblCommonStock	17500000	shares
CY2020Q1	atnf	Conversion Price Of Convertible Debt ConversionPriceOfConvertibleDebt	6
CY2019Q4	atnf	Conversion Price Of Convertible Debt ConversionPriceOfConvertibleDebt	6
CY2020Q1	atnf	Discounted Note Conversion Price DiscountedNoteConversionPrice	0.60	pure
CY2019Q4	atnf	Discounted Note Conversion Price DiscountedNoteConversionPrice	0.60	pure
CY2022Q1	atnf	Debt Principal Amount DebtPrincipalAmount	371178	usd
CY2022Q1	atnf	Debt Additional Amount DebtAdditionalAmount	300000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	6776686	usd
CY2022	atnf	Commitments Combined Amount CommitmentsCombinedAmount	4395000	cad
CY2022	atnf	Commitments Combined Amount CommitmentsCombinedAmount	3178025	usd
CY2022	atnf	Additional Sum Of Amount AdditionalSumOfAmount	2721036	usd
CY2021Q3	atnf	Settlement Paying Amount SettlementPayingAmount	2	usd
CY2022	atnf	Research And Developments Expenses ResearchAndDevelopmentsExpenses	0	usd
CY2021	atnf	Research And Developments Expenses ResearchAndDevelopmentsExpenses	443151	usd
CY2022	atnf	Agreement Period AgreementPeriod	P20Y
CY2021	atnf	Agreement Period AgreementPeriod	P2Y
CY2021Q3	atnf	Payment Of First Milestone PaymentOfFirstMilestone	97900	usd
CY2021Q3	atnf	Payment Of First Milestone PaymentOfFirstMilestone	70546	gbp
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	271931	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	223394	eur
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	152848	eur
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	11756	eur
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts	66223	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts	49207	eur
CY2021Q4	atnf	License Fee LicenseFee	13458	usd
CY2021Q4	atnf	License Fee LicenseFee	10000	eur
CY2021Q4	atnf	Maintenance Fee MaintenanceFee	4037	usd
CY2021Q4	atnf	Maintenance Fee MaintenanceFee	3000	eur
CY2018Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	450000	shares
CY2020Q1	us-gaap	Payments For Rent PaymentsForRent	0	eur
CY2021Q1	atnf	Percentage Of Consultant Bonus PercentageOfConsultantBonus	0.50	pure
CY2021Q1	atnf	Shares Issues SharesIssues	5035	shares
CY2021Q3	atnf	Shares Issues SharesIssues	3077	shares
CY2021Q3	us-gaap	Other Commitments Future Minimum Payments Remainder Of Fiscal Year OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear	15000000	usd
CY2002Q2	atnf	Consultant Fee ConsultantFee	23000	eur
CY2002Q2	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	4000	eur
CY2002Q2	us-gaap	Management Fee Payable ManagementFeePayable	19000	eur
CY2002Q2	atnf	Accrued Amount AccruedAmount	15000000	usd
CY2021Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	50000	usd
CY2021Q4	atnf	Shares Of License Agreement SharesOfLicenseAgreement	272	usd
CY2023Q1	atnf	Initial Term Of Agreement InitialTermOfAgreement	P3Y
CY2022	atnf	Consulting Services Payable ConsultingServicesPayable	60000	usd
CY2021Q4	atnf	Agreement Period AgreementPeriod	P1Y
CY2022	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	43750	usd
CY2022	atnf	Warrants Purchase Price WarrantsPurchasePrice	81	shares
CY2022	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	26325	shares
CY2021Q1	atnf	Additional Consideration Agreement Description AdditionalConsiderationAgreementDescription	As additional consideration for the CEO agreeing to enter into the agreement, the Company awarded him options to purchase 70,000 shares of the Company’s common stock, which have a term of 10 years, and an exercise price of $88.60 per share (the closing sales price on the date the board of directors approved the grant (February 26, 2021)). The options as subject to the Company’s 2020 Omnibus Incentive Plan and vest at the rate of (a) 1/5th of such options on the grant date; and (b) 4/5th of such options vesting ratably on a monthly basis over the following 36 months on the last day of each calendar month; provided, however, that such options vest immediately upon the CEO’s death or disability, termination without cause or a termination by the CEO for good reason (as defined in the agreement), a change in control of the Company or upon a sale of the Company.
CY2022	atnf	Percentage Of Salaries Available To Paid Bonus PercentageOfSalariesAvailableToPaidBonus	0.45	pure
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	313875	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	205500	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate	0.03	pure
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	0.20	pure
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	139500	usd
CY2022	atnf	Common Stock To Early Bird Valued CommonStockToEarlyBirdValued	79	usd
CY2022Q4	atnf	Percentage Of Targeted Amount PercentageOfTargetedAmount	0.50	pure
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	0.20	pure
CY2022Q2	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	221000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	100
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	968930	usd
CY2021	atnf	Allocated To Common Stock AllocatedToCommonStock	364812	usd
CY2021	atnf	Allocated To Warrant Liabilities AllocatedToWarrantLiabilities	604118	usd
CY2021Q4	atnf	Penalties For Event Of Default PenaltiesForEventOfDefault	174993	usd
CY2021Q4	atnf	Maximum Penalties For Event Of Defaults MaximumPenaltiesForEventOfDefaults	583310	usd
CY2021	atnf	Incurred Of Damages IncurredOfDamages	524979	usd
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	54.6
CY2021Q1	atnf	Accrued Interest Converted Amount AccruedInterestConvertedAmount	105850	usd
CY2017Q4	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	275000	usd
CY2017Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	11250	shares
CY2017Q4	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1973250	usd
CY2017Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	1750000	usd
CY2017Q4	us-gaap	Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1 DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1	223250	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	150
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q3	atnf	Placement Agent Fees And Offering Expenses PlacementAgentFeesAndOfferingExpenses	1120000	usd
CY2021	atnf	Original Issuance Discount OriginalIssuanceDiscount	7500	usd
CY2022Q3	atnf	Aggregate Shares AggregateShares	175000	shares
CY2022Q3	atnf	Warrants Purchase Price WarrantsPurchasePrice	0.0001	shares
CY2022	atnf	Prefunded Warrant Exercised PrefundedWarrantExercised	263	usd
CY2022Q4	atnf	Aggregate Shares AggregateShares	215000	shares
CY2022	atnf	Prefunded Warrant Shares PrefundedWarrantShares	1499286	shares
CY2022	atnf	Aggregate Shares AggregateShares	600	shares
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	48600	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	600	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	81
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	325	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	81
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	275	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	81
CY2022	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	22275000000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y
CY2021	atnf	Common Stocks Equivalents Shares Special Voting Shares CommonStocksEquivalentsSharesSpecialVotingShares	73224	shares
CY2020Q4	atnf	Special Voting Share Activity SpecialVotingShareActivity	73488	shares
CY2021	atnf	Special Voting Share Exchanged SpecialVotingShareExchanged	-73224	shares
CY2021Q4	atnf	Special Voting Share Activity SpecialVotingShareActivity	264	shares
CY2022Q4	atnf	Special Voting Share Activity SpecialVotingShareActivity	264	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2500	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.8
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y11M1D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	134550	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	96.34
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	137050	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	95.49
CY2021	atnf	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Option Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionWeightedAverageRemainingContractualTerm2	P9Y4M28D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	3525	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	25906	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	27.2
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	162956	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	84.63
CY2022	atnf	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Option Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionWeightedAverageRemainingContractualTerm2	P8Y7M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	93336	shares
CY2022Q4	atnf	Weighted Average Exercise Price Exercisable Ending WeightedAverageExercisePriceExercisableEnding	83.47
CY2022	atnf	Weighted Average Remaining Term1 Exercisable Ending WeightedAverageRemainingTerm1ExercisableEnding	P8Y6M
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	162956	shares
CY2022	atnf	Stock Options Exercisable Weighted Average Remainings Life In Years StockOptionsExercisableWeightedAverageRemainingsLifeInYears	P8Y6M
CY2022	atnf	Stock Options Exercisable Number Of Share StockOptionsExercisableNumberOfShare	93337	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease	79000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	88.6
CY2021Q1	atnf	Vest Rate VestRate	0.20	pure
CY2021Q1	atnf	Grant Rate Percentage GrantRatePercentage	0.80	pure
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4810527	usd
CY2021Q3	atnf	Granted Options GrantedOptions	P10Y
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease	21800	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	151.2
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2180375	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease	33750	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	79
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2077953	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease	5700	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	27.2
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	115936	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease	6707	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	27.2
CY2022	atnf	Shares Grant Dated Value SharesGrantDatedValue	6707	shares
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	13500	usd
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	261704	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0288	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.91	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2607501	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2852309	usd
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4202495	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P2Y2M8D
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-37727021	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-15078170	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1941987	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5269682	usd
CY2022	atnf	Income Tax IncomeTax	-39669008	usd
CY2021	atnf	Income Tax IncomeTax	-20347852	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	4057936	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1503577	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1343123	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	499136	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	353038	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	547944	usd
CY2022Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	5754097	usd
CY2021Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	2550657	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-4811348	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-2527453	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	942749	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	23204	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	-0.001	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	-0.005	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.066	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.052	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.237	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.058	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.107	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.064	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies Other EffectiveIncomeTaxRateReconciliationTaxContingenciesOther	-0.008	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.121	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.124	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.024	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.003	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13399384	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9395986	usd
CY2022	atnf	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	165476	usd
CY2022	atnf	Deferred Tax Assets Accrued Compensation Not Currently Deductible DeferredTaxAssetsAccruedCompensationNotCurrentlyDeductible	343787	usd
CY2021	atnf	Deferred Tax Assets Accrued Compensation Not Currently Deductible DeferredTaxAssetsAccruedCompensationNotCurrentlyDeductible	169222	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1588866	usd
CY2022Q4	atnf	Accrued Interests AccruedInterests	150502	usd
CY2021Q4	atnf	Accrued Interests AccruedInterests	146636	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	8125	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-1	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15656140	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9711843	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	368587	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	375671	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2332618	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	3267854	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	555880	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	639726	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3257085	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4283251	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	12399055	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	5428592	usd
CY2022Q4	atnf	Valuation Allowance ValuationAllowance	-15016414	usd
CY2021Q4	atnf	Valuation Allowance ValuationAllowance	-9072118	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2617359	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3643526	usd
CY2022	atnf	Stock Issued During Period Shares Reverse Stock Split StockIssuedDuringPeriodSharesReverseStockSplit		usd
CY2021	atnf	Stock Issued During Period Value Shares Issued Upon Exchange Of Common Stock Equivalents StockIssuedDuringPeriodValueSharesIssuedUponExchangeOfCommonStockEquivalents		usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	atnf	Deferred Tax Assets Beginning DeferredTaxAssetsBeginning	-9072118	usd
CY2021	atnf	Deferred Tax Assets Beginning DeferredTaxAssetsBeginning	-9709220	usd
CY2022	atnf	Change In Valuation Pursuant To The Tax Provision ChangeInValuationPursuantToTheTaxProvision	4811348	usd
CY2021	atnf	Change In Valuation Pursuant To The Tax Provision ChangeInValuationPursuantToTheTaxProvision	2527453	usd
CY2022	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-1132948	usd
CY2021	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	3164555	usd
CY2022	atnf	Deferred Tax Assets Beginning Ending DeferredTaxAssetsBeginningEnding	-15016414	usd
CY2021	atnf	Deferred Tax Assets Beginning Ending DeferredTaxAssetsBeginningEnding	-9072118	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.80	pure
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4811348	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2527453	usd
CY2022Q4	atnf	Accrued Expenses Related Parties AccruedExpensesRelatedParties	188159	usd
CY2021	atnf	Accrued Expense Related Parties AccruedExpenseRelatedParties	18370	usd
CY2022	atnf	Loans Payable Related Parties Amount LoansPayableRelatedPartiesAmount	0	usd
CY2021	atnf	Loans Payable Related Parties Amount LoansPayableRelatedPartiesAmount	81277	usd
CY2022	atnf	Research And Development Expenses Related Parties ResearchAndDevelopmentExpensesRelatedParties	240731	usd
CY2021	atnf	Research And Development Expenses Related Parties ResearchAndDevelopmentExpensesRelatedParties	2947536	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	5612	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	462580	usd
CY2021Q4	us-gaap	Bad Debt Reserve For Tax Purposes Of Qualified Lender BadDebtReserveForTaxPurposesOfQualifiedLender	338000	usd
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	1508	usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	atnf	Loans Payable Related Parties LoansPayableRelatedParties		usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges		usd
CY2022	atnf	Offering Costs Allocated To Warrant Liabilities OfferingCostsAllocatedToWarrantLiabilities		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.96
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-18.55
CY2022	atnf	Offering Costs Allocated To Warrant Liabilities OfferingCostsAllocatedToWarrantLiabilities		usd
CY2022	atnf	Change In Fair Value Of Accrued Issuable Equity ChangeInFairValueOfAccruedIssuableEquity		usd
CY2022	atnf	Increase Or Decrease In Accounts Payable Related Parties IncreaseOrDecreaseInAccountsPayableRelatedParties		usd
CY2022	atnf	Accrued Issuable Equitys AccruedIssuableEquitys		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022	atnf	Offering Costs In Connection With2021 Sale Of Stock And Warrants OfferingCostsInConnectionWith2021SaleOfStockAndWarrants		usd
CY2021	atnf	Offering Costs In Connection With July2022 Sale Of Common Stock And Common Warrants OfferingCostsInConnectionWithJuly2022SaleOfCommonStockAndCommonWarrants		usd
CY2021	atnf	Offering Costs In Connection With Sale Of Common Stock And Warrants OfferingCostsInConnectionWithSaleOfCommonStockAndWarrants		usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2021	atnf	Proceeds From Sale Of Common Stock1 ProceedsFromSaleOfCommonStock1		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	atnf	Proceeds From Exercise Of July2022 Prefunded Warrants ProceedsFromExerciseOfJuly2022PrefundedWarrants		usd
CY2021	atnf	Proceeds From Exercise Of December2022 Prefunded Warrants ProceedsFromExerciseOfDecember2022PrefundedWarrants		usd
CY2022	atnf	Common Stock Issued Upon Conversion Of Kbl Debt CommonStockIssuedUponConversionOfKBLDebt		usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2022	atnf	Deemed Dividend Beneficial Conversion Feature On Series A Convertible Preferred Stock DeemedDividendBeneficialConversionFeatureOnSeriesAConvertiblePreferredStock		usd
CY2022	atnf	Shares Issued Due To Impact Of Transfer Agent Reconciliation SharesIssuedDueToImpactOfTransferAgentReconciliation		usd
CY2022	atnf	Exchange Of Common Stock Equivalents For Common Stock ExchangeOfCommonStockEquivalentsForCommonStock		usd
CY2022	atnf	Shares Cancelled SharesCancelled		usd
CY2022	atnf	Reclassification Of Accrued Issuable Equity ReclassificationOfAccruedIssuableEquity		usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2021Q4	atnf	Accrued Issuable Equity Balance AccruedIssuableEquityBalance		usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2021Q4	atnf	Number Of Warrants Exercised NumberOfWarrantsExercised		shares
CY2021	atnf	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised
CY2021Q4	atnf	Number Of Warrants Cancelled NumberOfWarrantsCancelled		shares
CY2021	atnf	Weighted Average Exercise Price Cancelled WeightedAverageExercisePriceCancelled
CY2021	atnf	Number Of Warrants Expired NumberOfWarrantsExpired		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	atnf	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Life In Years Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLifeInYearsExercised
CY2022Q4	atnf	Number Of Warrants Cancelled NumberOfWarrantsCancelled		shares
CY2022	atnf	Weighted Average Exercise Price Cancelled WeightedAverageExercisePriceCancelled
CY2022	atnf	Number Of Warrants Expired NumberOfWarrantsExpired		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022	atnf	Related Party Loans RelatedPartyLoans		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
CY2021	atnf	Special Voting Share Issued SpecialVotingShareIssued		shares
CY2022	atnf	Special Voting Share Issued SpecialVotingShareIssued		shares
CY2022	atnf	Special Voting Share Exchanged SpecialVotingShareExchanged		shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2021	atnf	Weighted Average Remaining Term1 Granted WeightedAverageRemainingTerm1Granted
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested		usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021	atnf	Weighted Average Remaining Term1 Exercised WeightedAverageRemainingTerm1Exercised
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested		usd
CY2021	atnf	Number Of Options Expired NumberOfOptionsExpired		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021	atnf	Weighted Average Remaining Term1 Expired WeightedAverageRemainingTerm1Expired
CY2021	atnf	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expired SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021	atnf	Weighted Average Remaining Term1 Forfeited WeightedAverageRemainingTerm1Forfeited
CY2021	atnf	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited		usd
CY2022	atnf	Weighted Average Remaining Term1 Granted WeightedAverageRemainingTerm1Granted
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	atnf	Weighted Average Remaining Term1 Exercised WeightedAverageRemainingTerm1Exercised
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested		usd
CY2022	atnf	Number Of Options Expired NumberOfOptionsExpired		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022	atnf	Weighted Average Remaining Term1 Expired WeightedAverageRemainingTerm1Expired
CY2022	atnf	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expired SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	atnf	Weighted Average Remaining Term1 Forfeited WeightedAverageRemainingTerm1Forfeited
CY2022	atnf	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2022Q4	atnf	Intrinsic Value Exercisable Ending IntrinsicValueExercisableEnding		usd
CY2021Q1	atnf	Granted Options GrantedOptions	P10Y
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent		pure
CY2021	atnf	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization		usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001690080

Files In Submission

Name	View Source	Status
0001213900-23-025521-index-headers.html	Edgar Link	pending
0001213900-23-025521-index.html	Edgar Link	pending
0001213900-23-025521.txt	Edgar Link	pending
0001213900-23-025521-xbrl.zip	Edgar Link	pending
atnf-20221231.xsd	Edgar Link	pending
f10k2022ex10-59_180lifesci.htm	Edgar Link	pending
f10k2022ex21-1_180lifesci.htm	Edgar Link	pending
f10k2022ex23-1_180lifesci.htm	Edgar Link	pending
f10k2022ex31-1_180lifesci.htm	Edgar Link	pending
f10k2022ex31-2_180lifesci.htm	Edgar Link	pending
f10k2022ex32-1_180lifesci.htm	Edgar Link	pending
f10k2022ex32-2_180lifesci.htm	Edgar Link	pending
f10k2022ex4-6_180lifesci.htm	Edgar Link	pending
f10k2022_180lifesci.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
atnf-20221231_cal.xml	Edgar Link	unprocessable
atnf-20221231_def.xml	Edgar Link	unprocessable
atnf-20221231_pre.xml	Edgar Link	unprocessable
atnf-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_180lifesci_htm.xml	Edgar Link	completed
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATNF
180 Life Sciences Corp. Stock $atnf

2023 Q1 Form 10-K Financial Statement

#000121390023025521 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATNF 180 Life Sciences Corp. Stock $atnf

2023 Q1 Form 10-K Financial Statement

#000121390023025521 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATNF
180 Life Sciences Corp. Stock $atnf